Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 19/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590616 | 0.92 | GABRA1 (0.46) | GABRA1 | |
| SCHEMBL30694840 | 0.92 | GABRA1 (0.46) | GABRA1 | |
| SCHEMBL21591001 | 0.92 | GABRA1 (0.41) | GABRA1 | |
| SCHEMBL30694858 | 0.92 | GABRA1 (0.41) | GABRA1 | |
| SCHEMBL21590668 | 0.88 | GABRA1 (0.41) | GABRA1 | |
| SCHEMBL30694847 | 0.87 | GABRA1 (0.40) | GABRA1 | |
| SCHEMBL21590986 | 0.87 | GABRA1 (0.40) | GABRA1 | |
| SCHEMBL21590824 | 0.86 | GABRA1 (0.39) | GABRA1HTR2AHTR2BMRGPRX1 | |
| SCHEMBL21590424 | 0.86 | GABRA1 (0.39) | GABRA1 | |
| SCHEMBL21591006 | 0.85 | GABRA1 (0.36) | GABRA1HTR2AHTR2BMRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2019238633-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | GABRA1 4/4885HTR2A 479/4885HTR2B 332/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | GABRA1 4/4885HTR2A 513/4885HTR2B 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.